NCT07035938 T-cell Developmental Status in Patients With Malignant Hematological Tumors
| NCT ID | NCT07035938 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Condition | Hematologic Malignancy |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-06-22 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2025-06-22 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the immune status and prognosis of patients with malignant hematological tumors, thereby guiding clinical therapeutic strategies.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years; both genders included; expected survival \> 3 months; 2. Cohort 1: Patients with newly diagnosed or relapsed B-cell lymphoma confirmed by histopathology, bone marrow pathology, flow cytometry, morphology, and genetic testing; Cohort 2: Patients with newly diagnosed or relapsed multiple myeloma confirmed by the same methods; Cohort 3: Healthy volunteers; 3. Able to understand and voluntarily sign the informed consent form. Exclusion Criteria: 1. Significant pulmonary disease: Chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) \<50% of predicted normal value. Note: Suspected COPD cases require FEV1 testing; subjects with FEV1 \<50% of predicted must be excluded. Moderate/severe persistent asthma within the past 2 years, or currently uncontrolled asthma of any severity. (Note: Controlled intermittent or mild persistent asthma is permitted.) 2. Symptomatic congestive heart failure (NYHA Class II-IV), symptomatic/uncontrolled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) \>500 ms (Fridericia formula) at screening. 3. History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonitis, or severely impaired lung function. 4. HIV infection (positive HIV-1/2 antibodies) or known syphilis infection. 5. Unhealed wounds, fractures, gastroduodenal ulcers, persistent fecal occult blood positivity, ulcerative colitis, or other conditions at risk of gastrointestinal bleeding/perforation (as determined by the investigator). 6. Severe neurological/psychiatric disorders, immunodeficiency, hepatitis/cirrhosis, or other conditions deemed unsuitable for study participation by the investigator.
Frequently Asked Questions
Who can join the NCT07035938 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07035938 currently recruiting?
Yes, NCT07035938 is actively recruiting participants. Visit ClinicalTrials.gov or contact The First Affiliated Hospital of Xiamen University to inquire about joining.
Where is the NCT07035938 trial being conducted?
This trial is being conducted at Xiamen, China.
Who is sponsoring the NCT07035938 clinical trial?
NCT07035938 is sponsored by The First Affiliated Hospital of Xiamen University. The trial plans to enroll 75 participants.